Merck & Co. joins race for COVID-19 vaccines and therapies

Tuesday, May 26, 2020 - 21:10 in Health & Medicine

The firm will develop viral vector vaccines from IAVI and Themis Bioscience, and the experimental EIDD-2801 antiviral compound developed by Ridgeback Biotherapeutics

Read the whole article on C&EN

More from C&EN

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net